Open AccessImmuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused byLeishmania(Viannia)
Author(s) -
María Adelaida Gómez,
Adriavas,
Manuel Prieto,
Lina Giraldo-Parra,
Alexandra Cossio,
Neal Alexander,
Nancy Gore Saravia
Publication year - 2020
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciaa1206
Subject(s) - meglumine antimoniate , cutaneous leishmaniasis , medicine , leishmania , pharmacodynamics , pharmacology , immune system , pharmacokinetics , drug , peripheral blood mononuclear cell , immunology , leishmaniasis , biology , in vitro , parasite hosting , biochemistry , world wide web , computer science
Control of cutaneous leishmaniasis (CL) relies on chemotherapy, yet gaps in our understanding of the determinants of therapeutic outcome impede optimization of antileishmanial drug regimens. Pharmacodynamic (PD) parameters of antimicrobials are based on the relationship between drug concentrations/exposure and microbial kill. However, viable Leishmania persist in a high proportion of individuals despite clinical resolution, indicating that determinants other than parasite clearance are involved in drug efficacy.